trial

Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients

NCTId NCT01348100
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Completed
Enrollment 81 (actual)
Sponsored by Novartis Pharmaceuticals
Primary completion 2012-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Completed
Enrollment
81 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2011-04
Primary completion
2012-07
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Iloperidone

Sponsors

Novartis PharmaceuticalsLead Sponsor
Vanda PharmaceuticalsCollaborator

Sites

2 total
Glendale, United StatesPhiladelphia, United States

Linked catalysts

1
Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic — primary completion2012-07

Facts & assertions

4 sourced
Enrollment
81
Phase
PHASE1,PHASE2
Primary Completion Date
2012-07
Status
COMPLETED
relationships
The graph out of here
drug
Iloperidone
drug
lead_sponsor
Novartis Pharmaceuticals
company
collaborator
Vanda Pharmaceuticals
company
indication
Schizophrenia
indication
Schizophrenia
indication